Celldex Therapeutics Inc.

NASDAQ:CLDX   3:59:54 PM EDT
16.27
+0.07 (+0.43%)
Products, Regulatory, Other Pre-Announcement

Celldex Therapeutics Says First Patient Dosed In Phase 1B Study Of CDX-0159 In Patients With Chronic Spontaneous Urticaria

Published: 10/13/2020 12:50 GMT
Celldex Therapeutics Inc (CLDX) - Celldex Therapeutics Inc - Enrollment Opened & First Patient Dosed in Phase 1b Study of Cdx-0159 in Patients With Chronic Spontaneous Urticaria.
Celldex Therapeutics Inc - Study is Expected to Enroll Approximately 40 Patients With Csu Across Four Cohorts.
Celldex Therapeutics Inc - Results From Study Are Expected in Second Half of 2021.